Georg Karpel-Massler

List of Publications by Citations

66 papers	1,617 citations	25 h-index	38 g-index
71 ext. papers	1,975 ext. citations	5.8 avg, IF	4.63 L-index

#	Paper	IF	Citations
66	A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. *Oncotarget*, **2013**, 4, 502-30	3.3	131
65	Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?. *Molecular Cancer Research*, **2009**, 7, 1000-12	6.6	93
64	CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. *Oncotarget*, **2014**, 5, 8052-82	3.3	81
63	Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. *Nature Communications*, **2017**, 8, 1067	17.4	73
62	Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. *Biomedicines*, **2019**, 7,	4.8	69
61	A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers. *Clinical Cancer Research*, **2016**, 22, 4698-711	12.9	52
60	Inhibition of NF-B signaling ablates the invasive phenotype of glioblastoma. *Molecular Cancer Research*, **2013**, 11, 1611-23	6.6	51
59	TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. *Oncotarget*, **2015**, 6, 36456-71	3.3	48
58	Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. *Molecular Cancer Therapeutics*, **2013**, 12, 1783-95	6.1	47
57	Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. *Cancer Research*, **2017**, 77, 3513-3526	10.1	45
56	Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. *Clinical Cancer Research*, **2018**, 24, 5392-5406	12.9	43
55	Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo. *Oncotarget*, **2015**, 6, 14507-21	3.3	42
54	HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. *Journal of Clinical Investigation*, **2020**, 130, 3699-3716	15.9	41
53	PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma. *PLoS ONE*, **2014**, 9, e114583	3.7	37
52	Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo. *Oncotarget*, **2016**, 7, 33512-28	3.3	37
51	Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect. *Journal of Neuro-Oncology*, **2015**, 122, 21-33	4.8	36
50	RIST: a potent new combination therapy for glioblastoma. *International Journal of Cancer*, **2015**, 136, E173-87	7.5	35

49	A paired comparison between glioblastoma "stem cells" and differentiated cells. *International Journal of Cancer*, **2016**, 138, 1709-18	7.5	34
48	A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy. *Molecular and Cellular Therapies*, **2014**, 2, 32		33
47	Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo. *Oncotarget*, **2016**, 7, 12791-805	3.3	33
46	Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. *Anti-Cancer Agents in Medicinal Chemistry*, **2014**, 14, 313-8	2.2	32
45	BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma. *Oncotarget*, **2017**, 8, 29558-29573	3.3	29
44	A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy. *PLoS ONE*, **2015**, 10, e0131670	3.7	28
43	Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma. *Expert Opinion on Drug Discovery*, **2017**, 12, 1031-1040	6.2	27
42	Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma. *Clinical Cancer Research*, **2018**, 24, 3941-3954	12.9	25
41	The effects of PI3K-mediated signalling on glioblastoma cell behaviour. *Oncogenesis*, **2017**, 6, 398	6.6	24
40	Killing me softly--future challenges in apoptosis research. *International Journal of Molecular Sciences*, **2014**, 15, 3746-67	6.3	24
39	Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification. *Neurochemical Research*, **2017**, 42, 3382-3389	4.6	22
38	Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma. *Oncotarget*, **2017**, 8, 37140-37153	3.3	22
37	Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen. *Oncotarget*, **2017**, 8, 60727-60749	3.3	22
36	Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma. *Cancers*, **2012**, 4, 523-30	6.6	20
35	Compare and contrast: pediatric cancer versus adult malignancies. *Cancer and Metastasis Reviews*, **2019**, 38, 673-682	9.6	20
34	Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma. *British Journal of Cancer*, **2020**, 122, 1146-1157	8.7	19
33	Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. *British Journal of Pharmacology*, **2019**, 176, 3681-3694	8.6	18
32	Why dapsone stops seizures and may stop neutrophilsSdelivery of VEGF to glioblastoma. *British Journal of Neurosurgery*, **2012**, 26, 813-7	1	18

31	Current state and future perspective of drug repurposing in malignant glioma. *Seminars in Cancer Biology*, **2021**, 68, 92-104	12.7	18
30	Erlotinib in glioblastoma: lost in translation?. *Anti-Cancer Agents in Medicinal Chemistry*, **2011**, 11, 748-55	2.2	16
29	Cell Death Induction in Cancer Therapy - Past, Present, and Future. *Critical Reviews in Oncogenesis*, **2016**, 21, 253-267	1.3	15
28	Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?. *British Journal of Pharmacology*, **2011**, 164, 1393-6	8.6	14
27	Activation of LXR Receptors and Inhibition of TRAP1 Causes Synthetic Lethality in Solid Tumors. *Cancers*, **2019**, 11,	6.6	12
26	Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen. *Brain Sciences*, **2018**, 8,	3.4	12
25	Considering the Experimental use of Temozolomide in Glioblastoma Research. *Biomedicines*, **2020**, 8,	4.8	11
24	Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma. *Cancers*, **2020**, 12,	6.6	11
23	Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis. *Cellular Oncology (Dordrecht)*, **2019**, 42, 287-301	7.2	10
22	Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro. *Neurochemical Research*, **2017**, 42, 1543-1554	4.6	9
21	Cell death-based treatment of childhood cancer. *Cell Death and Disease*, **2018**, 9, 116	9.8	9
20	Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems. *Cells*, **2020**, 9,	7.9	9
19	A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. *Neuro-Oncology Advances*, **2021**, 3, vdab075	0.9	8
18	The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. *Breast Cancer: Targets and Therapy*, **2017**, 9, 495-514	3.9	7
17	Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells. *International Journal of Oncology*, **2018**, 53, 1881-1896	4.4	7
16	The limitations of targeting MEK signalling in Glioblastoma therapy. *Scientific Reports*, **2020**, 10, 7401	4.9	4
15	Ribozyme-mediated inhibition of 801-bp deletion-mutant epidermal growth factor receptor mRNA expression in glioblastoma multiforme. *Molecules*, **2010**, 15, 4670-8	4.8	4
14	Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. *Nature Communications*, **2021**, 12, 5203	17.4	4

List of Publications

13	Comment in Response to "Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy etc. by B. Kaina". *Biomedicines*, **2020**, 8,	4.8	3
12	EXTH-79. INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4 FOR RECURRENT GLIOBLASTOMA. *Neuro-Oncology*, **2017**, 19, vi90-vi90	1	3
11	In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma.. *Pharmaceuticals*, **2021**, 14,	5.2	3
10	A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen. *Brain Sciences*, **2020**, 10,	3.4	2
9	Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma. *Recent Patents on Anti-Cancer Drug Discovery*, **2011**, 6, 384-94	2.6	2
8	Rare Case of Sporadic Malignant Optic Pathway Glioma in 71-Year-Old Woman. *World Neurosurgery*, **2020**, 133, 413-415	2.1	2
7	Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma.. *Clinical Cancer Research*, **2022**, OF1-OF15	12.9	2
6	Methodological Approaches for Assessing Metabolomic Changes in Glioblastomas.. *Methods in Molecular Biology*, **2022**, 2445, 305-328	1.4	1
5	Block of Voltage-Gated Sodium Channels as a Potential Novel Anti-cancer Mechanism of TIC10. *Frontiers in Pharmacology*, **2021**, 12, 737637	5.6	1
4	Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma. *Cancers*, **2021**, 13,	6.6	1
3	MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. *Cancers*, **2022**, 14, 2563	6.6	1
2	ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells Independent of C-Myc Expression.. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 734699	5.7	0
1	Targeting super-enhancers reprograms glioblastoma central carbon metabolism. *Oncotarget*, **2021**, 12, 1309-1313	3.3	0